Replies to post #2001 on Enanta Pharmaceuticals Inc (ENTA)

[DewDiligence]

ENTA files preliminary shelf registration for unspecified amount of capital:

https://www.sec.gov/Archives/edgar/data/1177648/000156459021042633/enta-s3asr.htm

ENTA certainly isn’t planning to raise capital in the near future, so I wouldn’t read anything in particular into this filing.

[DewDiligence]

ENTA’s pro forma cash @9/30/21=$391.3M—a decrease of $16.9M since 6/30/21 (#msg-165355929).

The $391.3M figure above consists of: $282.8M of net current assets on the 9/30/21 balance sheet (https://www.sec.gov/ix?doc=/Archives/edgar/data/0001177648/000095017021004895/enta-20210930.htm page F-4); and $108.4M of marketable securities on the 9/30/21 balance sheet designated as long-term (e.g. bonds with a time to maturity greater than one year).

Note: Among the current assets is a $37.3M tax-refund receivable from the IRS, pursuant to a provision of the 2020 Cares Act that permits businesses to carry losses backward to offset previously paid US federal income taxes. This provision of the Cares Act has now expired, so ENTA will have no future tax refunds of this nature.